Invasive Fungal Infection Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Invasive Fungal Infection Market is segmented By Disease Type (Candidaemia and invasive Candidiasis, Intra-abdominal Candidiasis, Cryptococcal Meningitis, Esophageal candidiasis, Histoplasmosis acute pulmonary, Invasive Aspergillosis, Invasive Rhinosinusitis, Mucormycosis, and Others), By Drug Type (Polyenes, Triazoles, Echinocandins, Flucytosine, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 

Invasive Fungal Infection Market Report Overview

The invasive fungal infection market report analyzes the market shares, size, recent trends, future market outlook, and competitive intelligence. The demand for invasive fungal infection treatments is increasing due to the growing incidence of fungal infections and the development of novel antifungal drugs. The market is witnessing a surge in demand from region Europe, where the prevalence of these infections is high. The competitive rivalry is intensifying with major players such as Pfizer Inc., Gilead Sciences Inc., Merck & Co. Inc., and others actively operating in the market.

Invasive fungal infection (IFI) is one of the most common nosocomial infections and may result in invasive diseases in patients with various underlying diseases or other host factors.

Invasive Fungal Infection Market Scope and Summary

To Get a Free Sample Click here

Invasive Fungal Infection Market Dynamics and Trends

Increasing advanced and diverse technologies to explore emerging fungal pathogens are expected to drive market growth.

According to the American Society For Microbiology, published on 06 October 2020, infectious fungal agents include previously unidentified or rare pathogens that can cause unprecedented casualties in biodiversity, food security, and human health. Human activity influences, including the climate change crisis and globalized transport, are underlying factors shaping fungal adaptation to increased temperature and expanded geographical regions. Moreover, the emergence of novel antifungal-resistant strains linked to excessive antifungals (in the clinic) offers an additional challenge to control dangerous fungal outbreaks. Therefore, the alarming frequency of fungal infections in medicine requires effective research to understand the virulent nature of fungal pathogens and improve infection in susceptible hosts. Mycology-driven research has benefited from a contemporary and combined approach to omics technology, deepening the biological, biochemical, and biophysical understanding of these emerging fungal pathogens. For instance, the emergence of new fungal pathogens has unfolded in parallel with the genomic sequencing revolution, providing tools to help broaden the evolutionary knowledge of these pathogens' virulence, host range, and geographic expansion. Current approaches for genomic analysis include assembling a genome de novo for a novel species and resequencing using a complete reference genome to identify variants through comparisons. Multiple methods for assembly and resequencing are available, including short-read sequence technology (e.g., Illumina) and long-read technology beneficial for a repetitive genome (e.g., Pacific Biosciences and Oxford Nanopore). By capitalizing on such advancements in genomics technology, crucial information about the genome composition of rapidly emerging fungal species reveals gene family expansions and gene loss events, which outlines their functional potential for virulence and host infection. Thus, from the above statements, the market is expected to drive in the forecast period.

Increasing advancements in pipeline drugs are expected to drive the growth of the market

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials to treat invasive fungal infections caused by Candida Aspergillus and rare molds. It is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix shows a broad spectrum of in vitro activity against yeasts and molds, including difficult-to-treat pathogens. Because of its novel mechanism of action, manogepix maintains potency against many resistant strains, including echinocandin-resistant Candida and azole-resistant Aspergillus. Moreover, it is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolific, and Fusarium, with variable activity against Mucorales.

It shows its significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. Albicans, C. glabrata, C. Auris, C. tropicalis, Coccidioides immitis, and F. solani, as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum, and Rhizopus arrhizus. Additionally, clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles were observed, making Fosmanogepix an attractive option for treating invasive fungal infections.

Furthermore, on August 17, 2021, Cidara Therapeutics, Inc. and Mundipharma companies completed the recruitment of the pivotal Phase 3 ReSTORE trial for evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.

The consequences of immunosuppressive treatment are expected to hamper the market growth.

Immunosuppression is conducive to life-threatening invasive fungal infections due to many opportunistic fungal species that otherwise behave as commensals in humans or as saprophytes in the environment. Moreover, the antifungal activity of some immunosuppressive agents can lead to harmful microbiota changes and the selection of environmental species or isolates resistant to these drugs. Additionally, drug-drug interactions and genetic determinants of the patient might lead to suboptimal levels of drug accumulation and toxicity. Furthermore, azoles combined with calcineurin (e.g., tacrolimus and cyclosporin A) and mammalian target of rapamycin (e.g., sirolimus and everolimus) inhibitors increase their toxicities, especially nephrotoxicity. Thus, from the above factors, the market is expected to get hampered in the forecast period.

Pipeline Analysis

PEST Analysis  

COVID-19 Impact on Invasive Fungal Infection Market Growth

The COVID-19 pandemic is expected to impact the invasive fungal infection market positively. The Corona virus-19 disease, mostly affecting the respiratory system, has now emerged as a multi-organ disease. Moreover, a growing number of case reports and series describe opportunistic fungal infections in COVID-19 patients. Co-morbidities such as diabetes mellitus, coupled with immune dysfunction and the use of steroids, are hypothesized as the main causes. More recently, many cases of mucormycosis “black fungus” have been reported, particularly in Asian countries such as India. Mucormycosis is a rare angio-invasive illness caused by the fungi Mucorales, which is often seen in immune-compromised patients. Rhino-orbitocerebral, cutaneous, disseminated, gastrointestinal, and pulmonary forms of this unusual fungal infection exist. Thus, from the above factors, we can gauge that it has affected the market positively during Covid-19.

Invasive Fungal Infection Market Segment and Shares

The invasive Aspergillosis segment is expected to hold the largest market share in this market segment.

The invasive aspergillosis segment is estimated for the largest market share in 2020. The segment growth is attributed to the increasing prevalence of the fungus. For instance, according to the Centers for Disease Control and Prevention, Aspergillosis is an infection caused by a type of mold (fungus). The illnesses resulting from aspergillosis infection usually affect the respiratory system, but their signs and severity vary greatly. The most serious form of aspergillosis is invasive when the infection spreads rapidly from the lungs to the brain, heart, kidneys, or skin. Moreover, invasive aspergillosis occurs only in people whose immune systems are weakened due to cancer chemotherapy, bone marrow transplantation, or a disease of the immune system. Untreated, this form of aspergillosis may be deadly.

Additionally, patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience major lung damage due to viral replication and the ensuing cytokine storm and complex inflammatory processes. Whereas invasive aspergillosis is a well-described complication of severe influenza pneumonia, many intensivists overlook this superinfection. A recent study reported a 19% incidence among 432 patients admitted to an intensive care unit (ICU) for influenza-related acute respiratory failure. For instance, a large prospective study found that the one-year survival for people who had invasive aspergillosis was 59% among solid organ transplant recipients and 25% among stem cell transplant recipients. Therefore, in a systematic review of intensive care unit autopsy studies, aspergillosis was one of the top four most common diagnoses that likely lead to death. Thus, the segment is expected to hold the largest market share in the forecast period from the above statements.

Invasive Fungal Infection Market Geographical Analysis

North America region holds the largest market share in the global invasive fungal infection market.

North America accounted for the largest revenue share in 2020. The region’s growth is attributed to the high prevalence of invasive fungal infection, and rising public awareness of invasive fungal diseases are some of the factors expected to boost the market in the forecast period. For instance, according to the Centers for Disease Control and Prevention, published on September 25, 2020, Invasive fungal diseases cause significant morbidity and mortality. Awareness is necessary for early diagnosis and treatment. Public awareness of fungal diseases is low, and it is a concern because these diseases are associated with substantial illness, death, and economic cost. However, their true burden remains largely unquantified. Primary prevention of fungal diseases can be challenging, particularly those obtained via inhalation from the natural environment. Therefore, awareness is significant to help prevent severe disease because early diagnosis and treatment can prevent incorrect treatment and improve outcomes. For example, knowledge of coccidioidomycosis before inquiring about health care has been associated with a faster diagnosis.

Moreover, previous analyses show that coccidioidomycosis awareness is high in Arizona (97%) and lower in California (42%) (California Department of Public Health, unpublished data, 2020). More than 95% of cases occur in these two states, concentrated in Arizona’s Sonoran Desert and California’s southern San Joaquin Valley. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Invasive Fungal Infection Companies and Competitive Landscape

Major key players in the invasive fungal infection market are Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abbott, Merck & Co., Astellas Pharma Inc., and Scynexis Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the invasive fungal infection market globally. For instance, SCYNEXIS, on September 22, 2021,  announced the U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the first new antifungal class of therapy approved by the U.S. FDA for vaginal yeast infections in more than 20 years.

Cidara:

Overview:

Cidara is headquartered in San Diego, California. The company is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections.

Product Portfolio:

Cidara's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, micafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform.

Trending Topics

Interferons Market

Anti-malarial Drugs Market

Yeast Infection Treatment Market

Antifungal Drugs Market